COST-EFFECTIVENESS OF VEDOLIZUMAB COMPARED WITH USTEKINUMAB AS TREATMENT FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE IN THE UNITED STATES

被引：0
|
作者：
Zouraq, Azzabi, I [1 ]
Wilson, M. [2 ]
Hather, G. [3 ]
Curtis, R. [4 ]
Luo, M. [5 ]
Khalid, J. M. [4 ]
Minda, K. [1 ]
机构：
[1] Takeda Pharmaceut Int AG, Zurich, Switzerland
[2] RTI Hlth Sci, Res Triangle Pk, NC USA
[3] Takeda Pharmaceut, Cambridge, MA USA
[4] Takeda Dev Ctr Europe Ltd, London, England
[5] Takeda Pharmaceut Inc, Deerfield, IL USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PGI20
引用
收藏
页码：A183 / A183
页数：1
相关论文
共 50 条
  • [21] Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist
    Przemysław Holko
    Paweł Kawalec
    Andrzej Pilc
    PharmacoEconomics, 2018, 36 : 853 - 865
  • [22] Effectiveness and safety of vedolizumab induction with or without budesonide in patients with moderately to severely active Crohn’s disease in Europe: a retrospective observational study
    Roni Weisshof
    Stephan R. Vavricka
    Lieven Pouillon
    Fiona Braegger
    Montserrat Roset
    Nawal Bent-Ennakhil
    Marc Ferrante
    BMC Gastroenterology, 23
  • [23] Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn's Disease in China
    Zhou, Ting
    Sheng, Yanan
    Guan, Haijing
    ADVANCES IN THERAPY, 2021, 38 (08) : 4233 - 4245
  • [24] Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn’s Disease in China
    Ting Zhou
    Yanan Sheng
    Haijing Guan
    Advances in Therapy, 2021, 38 : 4233 - 4245
  • [25] Effectiveness and safety of vedolizumab induction with or without budesonide in patients with moderately to severely active Crohn's disease in Europe: a retrospective observational study
    Weisshof, Roni
    Vavricka, Stephan R.
    Pouillon, Lieven
    Braegger, Fiona
    Roset, Montserrat
    Bent-Ennakhil, Nawal
    Ferrante, Marc
    BMC GASTROENTEROLOGY, 2023, 23 (01)
  • [26] Comparative effectiveness of upadacitinib versus ustekinumab in patients with moderately to severely active Crohn's disease: a matching-adjusted indirect comparison
    Ma, C.
    Dubinsky, M. C.
    Axelrad, J.
    Anyanwu, S.
    Tran, J.
    Lacerda, A.
    Joshi, N.
    Griffith, J.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1866 - I1867
  • [27] Comparative effectiveness of upadacitinib versus ustekinumab in patients with moderately to severely active Crohn's disease: a matching-adjusted indirect comparison
    Thin, Lena
    Ma, Christopher
    Dubinsky, Marla
    Axelrad, Jordan
    Anyanwu, Samuel
    Tran, Jacinda
    Lacerda, Ana
    Joshi, Namita
    Griffith, Jenny
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 : 156 - 157
  • [28] Cost-effectiveness of vedolizumab IV vs. adalimumab SC for moderately to severely active ulcerative colitis
    Schultz, R.
    Diakite, I.
    Carter, J.
    Snedecor, S.
    Turpin, R.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S508 - S508
  • [29] COMPARATIVE SAFETY AND EFFECTIVENESS OF USTEKINUMAB AND VEDOLIZUMAB IN ELDERLY CROHN'S DISEASE PATIENTS
    Gebeyehu, Gerum Gashaw
    Fiske, Joseph
    Liu, Eleanor
    Limdi, Jimmy
    Davies, Mike
    Baig, Daniyal
    Liaros, Angela
    Gaba, Waqas
    Smith, Philip
    Subramanian, Sreedhar
    GUT, 2022, 71 : A47 - A48
  • [30] Vedolizumab: A Review of Its Use in Adult Patients with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
    Garnock-Jones, K. P.
    BIODRUGS, 2015, 29 (01) : 57 - 67
12345